title: Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome.
abstract: Akinetic crisis (AC) is akin to neuroleptic malignant syndrome (NMS) and is the most severe and possibly lethal complication of parkinsonism. Diagnosis is today based only on clinical assessments yet is often marred by concomitant precipitating factors. Our purpose is to evidence that AC and NMS can be reliably evidenced by FP/CIT single-photon emission computerized tomography (SPECT) performed during the crisis. Prospective cohort evaluation in 6 patients. In 5 patients, affected by Parkinson disease or Lewy body dementia, the crisis was categorized as AC. One was diagnosed as having NMS because of exposure to risperidone. In all FP/CIT, SPECT was performed in the acute phase. SPECT was repeated 3 to 6 months after the acute event in 5 patients. Visual assessments and semiquantitative evaluations of binding potentials (BPs) were used. To exclude the interference of emergency treatments, FP/CIT BP was also evaluated in 4 patients currently treated with apomorphine. During AC or NMS, BP values in caudate and putamen were reduced by 95% to 80%, to noise level with a nearly complete loss of striatum dopamine transporter-binding, corresponding to the "burst striatum" pattern. The follow-up re-evaluation in surviving patients showed a recovery of values to the range expected for Parkinsonisms of same disease duration. No binding effects of apomorphine were observed. By showing the outstanding binding reduction, presynaptic dopamine transporter ligand can provide instrumental evidence of AC in Parkinsonism and NMS.
authors.affiliation: From the Department of Radiology and Radiotherapy, Nuclear Medicine University G. d'Annunzio of Chieti-Pescara (GM, MN); Neurology Clinic, State Hospital (MC, LB, MO, AT); and Department of Neuroscience and Imaging and Aging Research Center, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy (LB, MO, AT).
authors.forename: G
authors.initials: G
authors.lastname: Martino
authors.forename: M
authors.initials: M
authors.lastname: Capasso
authors.forename: M
authors.initials: M
authors.lastname: Nasuti
authors.forename: L
authors.initials: L
authors.lastname: Bonanni
authors.forename: M
authors.initials: M
authors.lastname: Onofrj
authors.forename: A
authors.initials: A
authors.lastname: Thomas
mesh_terms: D000368:Aged; D001058:Apomorphine / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000473:pathology; D010300:Parkinson Disease / Q000175:diagnosis* / Q000473:pathology; D011446:Prospective Studies; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D018491:Dopamine Agonists; D050483:Dopamine Plasma Membrane Transport Proteins; D001058:Apomorphine
references.citation: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references.pmid: 1564476
references.citation: Brain Res. 2000 Jan 10;852(2):290-6
references.pmid: 10678755
references.citation: J Neurol. 2013 Aug;260(8):2182-4
references.pmid: 23835636
references.citation: J Cereb Blood Flow Metab. 2000 Nov;20(11):1604-9
references.pmid: 11083235
references.citation: Mov Disord. 2005 Dec;20(12):1671; author reply 1671-2
references.pmid: 16149099
references.citation: Neurology. 2003 Feb 11;60(3):381-9
references.pmid: 12580184
references.citation: Neurology. 2004 Mar 23;62(6 Suppl 4):S32-6
references.pmid: 15037670
references.citation: Eur J Neurol. 2014 Sep;21(9):1242-6
references.pmid: 24471704
references.citation: Mol Cell Biochem. 1997 Sep;174(1-2):255-9
references.pmid: 9309697
references.citation: J Neurol Sci. 2009 Jan 15;276(1-2):27-30
references.pmid: 18835490
references.citation: Case Rep Neurol. 2014 Nov 26;6(3):275-80
references.pmid: 25566059
references.citation: Mov Disord. 2000 Jul;15(4):692-8
references.pmid: 10928580
references.citation: JAMA. 2002 Apr 3;287(13):1653-61
references.pmid: 11926889
references.citation: Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1240-53
references.pmid: 17287959
references.citation: Brain. 2013 Aug;136(Pt 8):2393-404
references.pmid: 23625061
references.citation: Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1176-85
references.pmid: 15931516
references.citation: Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):434-42
references.pmid: 19838704
references.citation: Neurology. 2013 Aug 20;81(8):761-8
references.pmid: 23902707
references.citation: Neurology. 2010 Mar 16;74(11):885-92
references.pmid: 20181924
references.citation: Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1452-6
references.pmid: 16151764
references.citation: Neuromuscul Disord. 2008 Jun;18(6):460-4
references.pmid: 18502641
references.citation: Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50
references.pmid: 19838702
references.citation: J Neurol. 2012 Feb;259(2):251-60
references.pmid: 21750954
references.citation: Mov Disord. 2006 Apr;21(4):510-4
references.pmid: 16250023
references.citation: J Nucl Med. 1999 May;40(5):753-61
references.pmid: 10319746
references.citation: Ann Nucl Med. 2014 Nov;28(9):851-9
references.pmid: 24997753
references.citation: Pharmacoepidemiol Drug Saf. 2010 May;19(5):429-35
references.pmid: 20306454
references.citation: Mov Disord. 2003 Nov;18(11):1266-72
references.pmid: 14639666
references.citation: Neurology. 2005 Apr 12;64(7):1162-9
references.pmid: 15824341
references.citation: Neurology. 1994 Jul;44(7):1325-9
references.pmid: 8035939
references.citation: J Neuroimaging. 2014 May-Jun;24(3):257-65
references.pmid: 23323544
references.citation: Mov Disord. 1996 Nov;11(6):726-8
references.pmid: 8914102
references.citation: Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2364-70
references.pmid: 20697890
references.citation: Ann Neurol. 1993 May;33(5):512-7
references.pmid: 8098932
references.citation: Neurology. 2001 Jun 12;56(11):1559-64
references.pmid: 11402115
references.citation: Brain Behav. 2013 May;3(3):249-62
references.pmid: 23785657
references.citation: Neurology. 2004 Mar 23;62(6 Suppl 4):S8-11
references.pmid: 15037665
references.citation: Mov Disord. 1999 Nov;14(6):940-6
references.pmid: 10584667
references.citation: J Nucl Med. 2004 Oct;45(10):1694-7
references.pmid: 15471835